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Abstract Fibroblast growth factors (Fgfs) are proteins with
diverse functions in development, repair, and metabolism.
The human Fgf gene family with 22 members can be
classified into three groups, canonical, intracellular, and
hormone-like Fgf genes. In contrast to canonical and
intracellular Fgfs identified in invertebrates and vertebrates,
hormone-like Fgfs, Fgf15/19, Fgf21, and Fgf23, are
vertebrate-specific. The ancestral gene of hormone-like
Fgfs was generated from the ancestral gene of canonical
Fgfs by gene duplication early in vertebrate evolution.
Later, Fgf15/19, Fgf21, and Fgf23 were generated from the
ancestral gene by genome duplication events. Canonical
Fgfs act as autocrine/paracrine factors in an Fgf receptor
(Fgfr)-dependent manner. In contrast, hormone-like Fgfs act
as endocrine factors in an Fgfr-dependent manner. Canonical
Fgfs have a heparin-binding site necessary for the stable
binding of Fgfrs and local signaling. In contrast, hormone-like
Fgfs acquired endocrine functions by reducing their heparin-
binding affinity during their evolution. Fgf15/19 and Fgf23
require βKlotho and αKlotho as cofactors, respectively.
However, Fgf21 might physiologically require neither.
Hormone-like Fgfs play roles in metabolism at postnatal
stages, although they also play roles in development at
embryonic stages. Fgf15/19 regulates bile acid metabolism in
the liver. Fgf21 regulates lipid metabolism in the white
adipose tissue. Fgf23 regulates serum phosphate and active
vitamin D levels. Fgf23 signaling disorders caused by
hereditary diseases or tumors result in metabolic disorders. In
addition, serum Fgf19 or Fgf21 levels are significantly
increased bymetabolic disorders. Hormone-like Fgfs are newly
emerging and quite unique in their evolution and function.
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Introduction
Fibroblast growth factors (Fgfs) are proteins with diverse
functions in development, repair, and metabolism. The
prototypic Fgfs, Fgf1 (acidic Fgf) and Fgf2 (basic Fgf),
which were originally isolated as mitogens for fibroblasts
from the brain and pituitary, are widely expressed in
developing and adult tissues. Fgfs have since been isolated
as growth factors for cultured cells or identified by
homology-based polymerase chain reaction (PCR) and/
or homology-based searches in DNA databases. A few
Fgfs have also been identified in human hereditary diseases or
human/mouse tumors (Itoh 2007; Itoh and Ornitz 2008;
Krejci et al. 2009; Beenken and Mohammadi 2009).
The human Fgf gene family comprises 22 members
including Fgf1–Fgf23. Fgf15 has not been identified in
humans. Although the human genome has been completely
elucidated, no other member of the human Fgf family has
been identified. Human Fgfs, which comprise ∼150–300
amino acids, have a conserved ∼120-residue core with ∼30–
60% identity. Human Fgf genes were generated partly by
gene duplications early in metazoan evolution but mainly by
two large-scale genome duplication events early in vertebrate
evolution (Itoh and Ornitz 2004).
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The mouse is a widely used mammal model for studying
gene functions. The mouse Fgf family also comprises 22
members including Fgf1–Fgf23. Fgf19 has not been identi-
fied in mice. Fgf15 and Fgf19 are orthologs in vertebrates
(Itoh and Ornitz 2004). The zebrafish is also a widely used
vertebrate model for studying gene functions. The zebrafish
Fgf family comprises 28 members with several paralogs
generated by an additional genome duplication event shortly
after the teleost radiation (Itoh and Konishi 2007; The
Zebrafish Model Organism Databases, http://zfin.org).
The Fgf family can be divided into seven subfamilies by
phylogenetic and gene locus analyses. These subfamilies
can also be classified into three groups, the intracellular
Fgf11/12/13/14 subfamily, the hormone-like (endocrine)
Fgf19/21/23 subfamily, and the canonical Fgf subfamily
comprising the Fgf1/2/5, Fgf3/4/6, Fgf7/10/22, Fgf8/17/18,
and Fgf9/16/20 subfamilies, by their action mechanisms
(Itoh and Ornitz 2004, 2008). Canonical Fgfs mediate their
biological responses as extracellular proteins by binding to
and activating cell surface tyrosine kinase Fgf receptors
(Fgfrs) with heparin/heparan sulfate as a cofactor. They act
as local signaling molecules in an autocrine/paracrine
manner. In the development of multicellular organisms,
various signaling pathways are activated in a highly
coordinated manner to ensure proper morphogenesis.
Secreted signaling molecules such as canonical Fgfs, bone
morphogenic proteins (Bmps), Wnts, and Hedgehogs play
crucial roles in development by influencing the intracellular
signaling events of their neighbors from a distance (Itoh
and Ornitz 2004, 2008; Thisse and Thisse 2005; Mikels and
Nusse 2006). In contrast, intracellular Fgfs, Fgf11–Fgf14,
act as intracellular signaling molecules in an Fgfr-
independent manner. They interact with intracellular
domains of voltage-gate sodium channels and with a
neuronal mitogen-activated protein kinase scaffold protein,
islet-brain-2, and mainly play roles in neuronal functions at
postnatal stages (Goldfarb 2005; Goldfarb et al. 2007; Xiao
et al. 2007).
Canonical and intracellular Fgfs have been identified in
invertebrates and vertebrates. However, hormone-like Fgfs,
Fgf15/19, Fgf21, and Fgf23, have been identified in
vertebrates but not invertebrates (Itoh and Ornitz 2004;
Itoh and Konishi 2007). Hormone-like Fgfs also mainly
mediate their biological responses in an Fgfr-dependent
manner. However, they bind to Fgfrs with quite low affinity
even in the presence of heparin/heparan sulfate (Zhang et
al. 2006). Hormone-like Fgfs are unique in their evolution
and function. Several excellent reviews on the roles of
hormone-like Fgfs in metabolism have been published
(Fukumoto 2009; Kurosu and Kuro-o 2009; Kharitonenkov
2009; Razzaque 2009). This article provides a review of
hormone-like Fgfs, from their evolutionary history to their
roles in development, metabolism, and disease.
Identification of hormone-like Fgf genes
Fgf15/19
Pbx1 is a homeodomain transcription factor that has the
ability to form heterodimers with homeodomain proteins
encoded by the homeotic selector (Hox) gene complexes. In
pre B cell leukemias, Pbx1 is converted into a strong
transactivator by fusion to the activation domain of the
bHLH transcription factor E2A. The E2A-Pbx1 fusion
protein should therefore activate the transcription of
genes normally regulated by Pbx1. Fgf15 was originally
identified as a downstream target of the chimeric homoedo-
main oncoprotein E2A-Pbx1 in mice (McWhirter et al. 1997).
A new human Fgf was identified by a DNA database
search with the conserved amino acid core of known Fgfs.
As the human Fgf is not highly similar (less than 55%
amino acid identity) to any other known Fgfs, it was named
Fgf19 (Nishimura et al. 1999; Xie et al. 1999). However,
the Fgf19 gene was later found to be the human ortholog of
mouse Fgf15 based on conserved synteny around their loci
(Itoh and Ornitz 2004). Only the mouse and rat orthologs
were named Fgf15. The orthologs in other vertebrates were
named Fgf19.
Fgf21
Fgf21 was originally identified in mice and humans by
homology-based PCR with the conserved amino acid core
of human Fgf19 (Nishimura et al. 2000). Later, human
Fgf21 was identified as a stimulator of glucose uptake in
mouse 3 T3-L1 adipocytes by a glucose uptake assay to
search for novel proteins with therapeutic potential to treat
diabetes mellitus (Kharitonenkov et al. 2005). Fgf21 was
also identified as a gene inducible by fasting or a high-fat,
low-carbohydrate ketogenic diet in mice (Inagaki et al.
2007; Badman et al. 2007)
Fgf23
Fgf23 was originally identified in mice and humans by a
DNA database search with the conserved amino acid core
of mouse Fgf15 (Yamashita et al. 2000). Human Fgf23 was
simultaneously identified as a gene responsible for autoso-
mal dominant hypophosphatemic rickets (ADHR) (ADHR
consortium 2000). ADHR is characterized by low serum
phosphate levels, rickets, osteomalacia, lower extremity
deformities, short stature, bone pain and dental abscesses.
Later, human Fgf23 was identified as a causative humoral
protein for human tumor-induced osteomalacia (TIO)
(Shimada et al. 2001). TIO is a paraneoplasitc disease
characterized by hypophosphatemia caused by renal phos-
phate wasting.
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Identification of the Fgf19/21/23 gene subfamily
Although Fgf15/19, Fgf21, and Fgf23 are not very similar
(∼22–35% amino acid identity), phylogenetic and gene
locus analyses indicate that they are all members of the
Fgf19/21/23 subfamily (Itoh and Ornitz 2004, 2008).
Evolutionary history of hormone-like Fgf genes
in vertebrates
The Fgf signaling system has been conserved throughout
metazoan evolution. Most ancestral genes of the human Fgf
subfamilies have been identified in the ascidian, Ciona
intestinalis. Ascidians belong to the subphylum Urochordata,
the earliest branch in the phylum Chordata (Satou et al.
2002). These results indicate that most ancestral genes of the
Fgf subfamilies were generated by gene duplication events
early in metazoan evolution. The evolutionary history of the
Fgf family has been proposed (Fig. 1) (Itoh and Ornitz 2004,
2008). An ancestral gene of the intracellular Fgf subfamily,
Fgf13-like, is an ancestral gene of the Fgf family. An
ancestral gene of the canonical Fgf subfamily, Fgf4-like, was
generated from Fgf13-like by gene duplication during the
early stages of metazoan evolution. In contrast, no ancestral
gene of the hormone-like Fgf19/21/23 subfamily has been
identified in Ciona intestinalis. The ancestral gene, Fgf19-
like, was generated from Fgf4-like by local gene duplication
early in vertebrate evolution. Later, Fgf19, Fgf21, and Fgf23
were generated from Fgf19-like by two large-scale genome
duplication events (Itoh and Ornitz 2004; Itoh and Ornitz
2008). The evolutionary history suggests that hormone-like
Fgfs are vertebrate-specific.
Fgf15/19 and Fgf23 have been identified in all vertebrates
examined including teleosts, amphibians, reptiles, birds, and
mammals. Fgf21 has also been identified in most vertebrates
though not birds. Fgf21 might have been lost in the bird
lineage (Itoh 2007; Itoh, unpublished observation). Intracel-
lular and canonical Fgf subfamilies have several teleost-
specific paralogs, which were generated by an additional
teleost-specific genome duplication event, in zebrafish.
However, the hormone-like Fgf subfamily has no teleost-
specific paralog in zebrafish (Itoh and Konishi 2007).
Canonical Fgfs have a heparin-binding site. The site is
necessary for the stable binding of Fgfrs and local
signaling in an autocrine/paracrine manner. In contrast,
hormone-like Fgfs have endocrine functions with reduced
heparin-binding affinity (Goetz et al. 2007). Hormone-
like Fgfs acquired systemic signaling in an endocrine
manner during their evolution (Itoh and Ornitz 2008).
Roles of hormone-like Fgfs in development
and metabolism
Fgf15/19
In mice, the expression of Fgf15 exhibits a regionally
restricted pattern in the developing nervous system, suggest-
ing that Fgf15 has roles in regulating cell division and
patterning within specific regions of the embryonic brain,
spinal cord, and sensory organs (McWhirter et al. 1997).
Transgenic mice over-expressing human Fgf19 showed a
significant and specific reduction in fat mass and an increase
in energy expenditure, indicating potential roles for Fgf19 in
energy metabolism (Tomlinson et al. 2002).
To examine the physiological roles of Fgf15 in vivo,
Fgf15 knockout mice were generated. The mice survived at
a normal Mendelian ratio until embryonic day (E) 10.5, but,
then gradually died. Most of them had died by postnatal
day (P) 7. Heart defects were observed in the embryonic
stages, indicating that Fgf15 is required for proper
Fig. 1 Evolutionary history of
the Fgf gene family. Fgf13-like
is an ancestral gene of the Fgf
family. Fgf4-like is an ancestral
gene of the canonical Fgf
family. Fgf4-like was generated
from Fgf13-like by gene
duplication. Fgf15/19-like, an
ancestral gene of the
hormone-like Fgf subfamily,
was generated from Fgf4-like by
local gene duplication early in
vertebrate evolution. Later,
Fgf15/19, Fgf21, and Fgf23
were generated by two
large-scale genome duplication
events during the evolution of
early vertebrates
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morphogenesis of the cardiac outflow tract during embryonic
development (Table 1) (Vincentz et al. 2005). Fgf19
knockdown zebrafish embryos were also generated by the
injection of Fgf19 Morpholino antisense oligonucleotides.
Their phenotypes show essential roles of Fgf19 in the
forebrain, lens, and retina during embryonic development
(Table 1) (Miyake et al. 2005; Nakayama et al. 2008).
These results indicate that Fgf15/19 acts as a growth/
differentiation factor in the heart and brain at embryonic
stages.
Although most Fgf15 knockout mice die by P7, a few
survive with a normal appearance. Hepatic cholesterol 7α-
hydroxylase (Cyp7a1) gene expression is increased in the
surviving mice. Cyp7a1 catalyzes the first and rate-limiting
step in the classical pathway of bile acid synthesis. Fecal
bile acid excretion is increased in Fgf15 knockout mice
(Inagaki et al. 2005). A similar phenotype is observed in
Fgfr4 knockout mice (Yu et al. 2000). The liver and
intestine play crucial roles in maintaining bile acid
homeostasis. Fgf15 and Fgfr4 are expressed in the intestine
and liver, respectively. These results indicate that intestinal
Fgf15 plays a crucial role in regulating hepatic bile acid
synthesis at postnatal stages by activating hepatic Fgfr4 in an
endocrine manner (Table 1 and Fig. 2) (Inagaki et al. 2005).
Fgf21
In mice, Fgf21 is most abundantly expressed in the liver.
Fgf21 is also expressed in the pancreas, white adipose
tissue, and muscle (Nishimura et al 2000; Kharitonenkov
and Shanafelt 2009). Potential roles of Fgf21 in energy
metabolism were first shown by experiments in vitro. Fgf21
stimulated glucose uptake in cultured mouse and human
adipocytes (Kharitonenkov et al. 2005). The phenotypes of
Fgf21 transgenic mice with over-expression in the liver also
indicated potential roles in energy metabolism including
improved insulin sensitivity and reduced serum triglycerides
levels (Kharitonenkov et al. 2005).
Mammals have evolved complex metabolic responses to
fasting. During fasting, nonesterified fatty acid (NEFA) is
released from the white adipose tissue into the liver where it
is converted to acetyl-CoA by oxidation. Hepatocytes
synthesize ketone bodies from acetyl-CoA. Ketone bodies
become the predominant energy source for the brain during
fasting. Peroxisome proliferator-activated receptor α
(PPARα), a nuclear receptor activated by NEFA, is crucial
to the normal adaptive response to fasting. Ketogenesis in
the liver during fasting is greatly impaired in PPARα
knockout mice (Kersten et al. 1999; Leone et al. 1999).
Hepatic Fgf21 expression is induced directly by PPARα in
response to fasting. The phenotypes of Fgf21 transgenic
mice indicate that Fgf21 stimulates lipolysis in the white
adipose tissue and ketogenesis in the liver (Inagaki et al.
2007). The expression of Fgf21 was also induced in the
liver by a high-fat, low-carbohydrate ketogenic diet. In
addition, adenoviral knockdown of hepatic Fgf21 in mice
fed the ketogenic diet caused reduced serum ketone body
levels, fatty liver, and lipemia (Badman et al. 2007).
Hepatic triglyceride levels were also significantly decreased
in Fgf21 transgenic mice (Inagaki et al. 2007). These results
suggest that Fgf21 acts as a metabolic regulator of lipolysis
in the white adipose tissue and is required for ketogenesis
and triglyceride clearance in the liver.
To elucidate the physiological roles of Fgf21, Fgf21
knockout mice were generated. The mice were viable,
fertile, and seemingly normal. They showed hypertrophy of
adipocytes and decreased lipolysis in adipocytes. Serum
NEFA levels were significantly decreased, although serum
glucose and triglyceride levels were essentially unchanged.
In contrast, fasting Fgf21 knockout mice showed increased
lipolysis in adipocytes and increased serum NEFA levels.
These results indicate that Fgf21 stimulates lipolysis in the
white adipose tissue during feeding but inhibits it during
fasting. Unexpectedly, serum ketone levels were increased
by fasting in Fgf21 knockout mice, indicating that
ketogenesis was not impaired (Hotta et al. 2009). These
results indicate that Fgf21 regulates lipolysis in adipocytes
in response to the metabolic state but is not required for
ketogenesis or triglyceride clearance in the liver (Table 1).
However, Fgf21 knockout mice fed a ketogenic diet
showed partial impairments in ketogenesis and glucose
control (Badman et al. 2009).
Peroxisome proliferation-activated receptor γ coactivator-
1α (Pgc-1α), a transcriptional coactivator, interacts with
several DNA-binding proteins to regulate metabolism in
response to changes in nutritional status. Fgf21 induces Pgc-
1α expression in the liver. Fgf21 cannot induce gluconeo-
genic gene expression in Pgc-1α knockout mice. In addition,
Fgf21 knockout mice did not fully express Pgc-1α in
response to prolonged fasting and exhibited impaired gluco-
genesis and ketogenesis (Potthoff et al. 2009). These results
indicate that the metabolic actions of Fgf21 are mediated
in part through Pgc-1α. However, as described above, it
Table 1 Roles of hormone-like Fgfs in mice and zebrafish
Mice Zebrafish
At embryonic stages




Fgf15/19 Bile acid metabolism -
Fgf21 Lipid metabolism -
Fgf23 Phosphate/vitamin D metabolism -
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has also been reported that Fgf21 is not required for
glucogenesis and ketogenesis in the liver (Hotta et al.
2009).
Fgf21 regulates the insulin-independent transport of
glucose in cultured 3 T3-L1 adipocytes. Functional inter-
play between the Fgf21 and peroxisome proliferation-
activated receptor γ (PPARγ) pathways leads to a marked
stimulation of glucose transport (Moyers et al. 2007). These
results suggest a novel synergy between Fgf21 and PPARγ
homeostasis.
Fgf21 stimulates insulin gene expression but not
glucose-induced insulin secretion in isolated rat pancreatic
islets. Although Fgf21 has no effect on islet cell prolifer-
ation, it preserves β-cell function and survival (Wente et al.
2006). Fgf21 expression was markedly increased in mouse
pancreatic acinar cells during cerulein-induced pancreatitis
and following injury in vitro. Fgf21 transgenic mice
exhibited decreased serum amylase levels and decreased
pancreatic stellate cell activation. In addition, Fgf21
knockout mice showed increased serum amylase levels
and tissue damage (Johnson et al. 2009). These results
indicate a function of Fgf21 as an immediate response gene
protecting pancreatic acini from overt damage.
Starvation inhibits growth by blocking the growth
hormone/insulin-like growth factor I (Igf-I) signaling
pathway (Thissen et al. 1999). Fgf21 transgenic mice are
40–50% smaller than their wild-type counterparts (Inagaki
et al. 2008). Fgf21 causes resistance to growth hormone in
the liver. Fgf21 reduces concentrations of the active form of
signal transducer and activator of transcription 5, a major
mediator of growth hormone actions, and causes
corresponding decreases in the expression of its target
genes including Igf-1. Fgf21 also induces the hepatic
expression of genes encoding IGF-1-binding protein 1 and
suppressor of cytokine signaling 2, which blunt growth
hormone signaling (Inagaki et al. 2008). These results
indicate a central role for Fgf21 in inhibiting growth as part
of its broader role in inducing the adaptive response to
starvation. However, body size and tibia length are
essentially unchanged in Fgf21 knockout mice (Hotta et al
2009). In addition, growth hormone signaling in the liver
was essentially unaffected in Fgf21 knockout mice by
normal feeding or fasting for 24 h (Itoh et al. unpublished
observation). These results indicate that Fgf21 is not a
major physiological regulator for growth hormone signaling
in the liver.
Fig. 2 Action mechanisms of hormone-like Fgfs and regulatory
mechanisms of their gene expression. (Fgf15) Intestinal Fgf15
expression is regulated by bile acid produced in the liver. The
ligand-bound FXR forms a heterodimer with RXRs and induces the
expression of Fgf15. The Fgf15 suppresses the expression of Cyp7a1
in the liver by activating the βKlotho-Fgfr4 complex. The regulatory
process forms a negative feedback loop in the regulation of bile acid
homeostasis by Fgf15. (Fgf21) Hepatic Fgf21 expression is induced
by the activation of PPARα. NEFA binds to and activates PPARα.
The ligand-bound PPARα forms a heterodimer with RXRs and
induces the expression of Fgf21. However, the regulatory mechanism
of Fgf21 expression remains unclear. (Fgf23) Active vitamin D binds
the vitamin D receptor (VDR). The ligand-bound VDR forms a
heterodimer with retinoid X receptors (RXRs) and induces the
expression of Fgf23. The increased Fgf23 suppresses the expression
of Cyp27b1 and induces the expression of Cyp24 by activating the
αKlotho-Fgfr1c complex. The regulatory process forms a negative
feedback loop in the regulation of vitamin D homeostasis
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Torpor, the controlled lowering of metabolic rates, body
temperature, and physical activity, is an adaptation that
allows various mammals to cope with periods of low food
availability (Melvin and Andrews 2009). Fgf21 transgenic
mice show torpor-like phenomena such as hypoglycemia,
ketosis, and hypothermia (Inagaki et al. 2007). However,
fasting-induced hypothermia and locomotor activity were
essentially unchanged in Fgf21 knockout mice (Oishi et al.
2010). These results indicate that Fgf21 is not a major
physiological regulator for the hypothermia that is associated
with the early stages of fasting.
Fgf21 knockdown zebrafish embryos were also generated
by injection of Fgf21 Morpholino antisense oligonucleotides.
The embryos lacked erythroid and myeloid cells, indicating
that Fgf21 is essential for hematopoiesis in zebrafish. The
potential action mechanism of Fgf21 indicates an essential
role in hematopoiesis as a differentiation factor (Table 1)
(Yamauchi et al. 2006).
Fgf23
Fgf23 is mainly expressed in the bone. Fgf23 decreases
serum phosphate levels (Shimada et al. 2004). Type 2a and
2c sodium-phosphate cotransporters (NaPi-2a and NaPi-2c)
mediate proximal tubular phosphate reabsorption in the
kidney. Fgf23 suppresses the expression of NaPi-2a and
NaPi-2c in proximal tubular cells. Serum phosphate levels
are decreased by their suppression. In addition, Fgf23 also
suppresses the expression of Cyp27b1 (1α-hydroxylase)
and stimulates the expression of Cyp24 (24-hydroxylase).
1α-hydrooxylase and 24-hydroxylase mediate the synthesis
of active vitamin D and degrade active vitamin D,
respectively. By altering these gene expression levels,
Fgf23 decreases levels of active vitamin D in serum. As
active vitamin D stimulates intestinal phosphate reabsorption,
decreased levels result in decreased serum phosphate levels
(Table 1) (Shimada et al. 2004).
To examine the physiological roles of Fgf23 in mice,
Fgf23 knockout mice were generated (Shimada et al. 2004).
The phenotypes of these mice mirror ADHR and TIO
phenotypes. The mice showed hyperphosphatemia and
increased active vitamin D levels, indicating that Fgf23 is
a physiological regulator for phosphate and active vitamin
D levels in serum.
Action mechanism of hormone-like Fgfs with Klothos
αKlotho
αKlotho was originally identified as a gene with a loss-
of-function mutation in a mouse strain that developed
multiple aging-like phenotypes (Kuro-o et al. 1997). The
phenotypes are essentially similar to those of Fgf23
knockout mice (Shimada et al. 2004). These results
indicate that Fgf23 and Klotho may function in a common
signal transduction pathway. αKlotho is a 130-kDa single-
pass transmembrane protein with a short cytoplasmic
domain (10 amino acids). The extracellular domain has two
homologous domains with sequence similarity to β-
glucosidase. However, β-glucosidase-like activity is not
detected in αKlotho (Kuro-o et al. 1997). In cultured cells,
αKlotho efficiently bound to Fgfrs, Fgfr1, and Fgfr3 but not
to Fgfr2. αKlotho significantly enhanced the ability of Fgf23
to induce phosphorylation of a substrate of the Fgf receptor
and Erk in cultured cells (Kurosu et al. 2006). Alternative
splicing in the third immunoglobulin-like domain occurs in
Fgfr1, Fgfr2, and Fgfr3 but not in Fgfr4. αKlotho most
efficiently binds to and activates Fgfr1c among several
isoforms of Fgfrs in cultured cells (Urakawa et al. 2006).
These results indicate that Fgf23 activates Fgfr1c, which
forms a complex with αKlotho (Fig. 2).
βKlotho
βKlotho is a protein that shares structural identity (41%
amino acid identity) and characteristics with αKlotho.
βKlotho is expressed predominantly in the liver, pancreas,
and adipose tissue (Ito et al 2000). The synthesis and
excretion of bile acids are dramatically increased in βKlotho
knockout mice. In addition, βKlotho knockout mice exhibit
resistance to gallstone formation (Ito et al. 2005). Their
phenotypes overlap those of Fgfr4 knockout mice (Yu et al.
2000) and viable Fgf15 knockout mice (Inagaki et al. 2005),
indicating that Fgf15/19, Fgfr4, and βKlotho are essential
components in the regulation of bile acid synthesis (Fig. 2).
Fgf19 can bind to the βKlotho-Fgfr4 complex in cultured
cells. Fgf19 also activates Fgf signaling in hepatocytes that
primarily express Fgfr4 and reduces the expression of
Cyp7a1 encoding the rate-limiting enzyme for bile acid
synthesis (Kurosu et al. 2007).
As described above, Fgf15/19 plays roles in development
as a growth/differentiation factor (Vincentz et al. 2005;
Miyake et al. 2005; Nakayama et al. 2008). However, it
remains unclear whether βKlotho is required for Fgf15/19
signaling at embryonic stages.
βKlotho is also essential for Fgf21 signaling in
cultured cells (Ogawa et al. 2007; Kharitonenkov et al.
2008; Suzuki et al. 2008). However, Fgf21 knockout
mouse phenotypes (Hotta et al. 2009) are distinct from
βKlotho knockout mouse phenotypes (Ito et al. 2005). In
addition, administration of recombinant human Fgf21 to
βKlotho knockout mice indicates that Fgf21 signals are
transduced in the absence of βKlotho (Tomiyama et al.
2010). These results indicate the existence of a βKlotho-
independent Fgf21 signaling pathway in which undefined
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cofactors might be involved (Fig. 2). One-to-one func-
tional interactions such as αKlotho/Fgf23, βKlotho/
Fgf15/19, and undefined cofactor/Fgf21 would result in
tissue-specific signal transduction of the hormone-like
Fgf subfamily (Tomiyama et al. 2010). The beneficial
pharmacological effects of Fgf21 such as decrease of
blood glucose and lipid levels and suppression of weight
gain have been observed in mice after its administration
or its over-expression by transgene (Kharitonenkov
2009). However, as the pharmacological effects have not
been examined in βKlotho knockout mice, the involve-
ment of βKlotho in the pharmacological effects remains
unclear.
Regulatory mechanism of hormone-like Fgf gene
expression
Fgf15
Intestinal Fgf15 expression is regulated by bile acid
produced in the mouse liver. This bile acid is released into
the intestinal lumen and binds to its nuclear receptor, the
farnesoid X receptor (FXR), in intestinal epithelial cells.
The ligand-bound FXR forms a heterodimer with retinoid X
receptors (RXRs) and induces the expression of Fgf15. The
Fgf15 suppresses the expression of Cyp7a1 in the liver by
activating Fgfr4. Cyp7a1 catalyzes the rate-limiting step in
bile acid synthesis in the liver. The regulatory process
forms a negative feedback loop in the regulation of bile
acid homeostasis by Fgf15 (Fig. 2) (Inagaki et al. 2005;
Kuro-o 2008).
Fgf21
Hepatic Fgf21 expression is greatly induced in wild-type
mice but not PPARα knockout mice by fasting for 24 h. In
addition, hepatic Fgf21 expression is also greatly induced
by GW7647, a PPARα—selective agonist (Inagaki et al.
2007). These results indicate that hepatic Fgf21 expression
is induced by the activation of PPARα. NEFA also binds to
and activates PPARα. The ligand-bound PPARα forms a
heterodimer with RXRs and induces the expression of
Fgf21. Fasting increases the amounts of NEFA released
from adipocytes. Hepatic Fgf21 expression during fasting
might be induced through the activation of PPARα by the
NEFA (Moore 2007; Kuro-o 2008). However, although
hepatic Fgf21 expression is greatly induced in wild-type
mice by fasting for 24 h, serum NEFA levels are essentially
unchanged (Badman et al. 2007; Hotta et al. 2009). These
results indicate that PPARα is not activated by NEFA
during fasting for 24 h. The regulatory mechanism of Fgf21
expression remains unclear (Fig. 2).
Fgf23
Active vitamin D produced in the kidney increases the
expression of Fgf23 in the bone and serum Fgf23 levels in
mice. Active vitamin D binds the vitamin D receptor (VDR).
The ligand-bound VDR forms a heterodimer with retinoid X
receptors (RXRs) and induces the expression of Fgf23 in the
bone. The Fgf23 suppresses the expression of Cyp27b1 and
induces the expression of Cyp24 in the kidney (Shimada et al
2004). Cyp27b1 and Cyp24 encode enzymes, 1a-
hydroxylase and 24-hydroxylase, which synthesize and
inactivate active vitamin D, respectively. The suppression
of Cyp27b1 expression and induction of Cyp24 expression
by Fgf23 result in decreased levels of active vitamin D in
serum. The regulatory process forms a negative feedback
loop in the regulation of vitamin D homeostasis (Fig. 2)
(Tsujikawa et al. 2003; Moore 2007; Kuro-o 2008).
Roles of hormone-like Fgfs in disease
Fgf19
Serum Fgf19 levels are markedly elevated in patients with
extrahepatic cholestasis caused by a pancreatic tumor.
Although not expressed in the normal liver, Fgf19 is
abundantly expressed in the liver of cholestatic patients.
This is accompanied by a number of adaptations aimed at
protecting the liver against bile salt toxicity. Fgf19
signaling may be involved in some of these adaptations
(Table 2) (Schaap et al. 2009). Serum Fgf19 levels are also
significantly increased in patients on chronic hemodialysis
(Table 2) (Reiche et al. 2010). Hepatic lipid metabolism is
disturbed in patients with nonalcoholic fatty liver disease
(NAFLD). The hepatic response to Fgf19 is impaired in
NAFLD patients with insulin resistance. This impaired
hepatic response to Fgf19 may contribute to the disturbance
of lipid homeostasis in NAFLD (Table 2) (Schreuder et al.
2010).
Fgf21
Serum Fgf21 levels are increased in patients with type 2
diabetes and obesity (Table 2) (Zhang et al 2008; Chen et al
2008; Mraz et al 2009). They are also increased in patients
with Cushing’s syndrome (Table 2) (Durovcová et al. 2010).
In contrast, serum Fgf21 levels are decreased in patients with
anorexia nervosa (Table 2) (Dostálová et al. 2008).
Fgf23
Hereditary Fgf23 signaling disorders result in metabolic
disorders (Razzaque 2009). AHDR is caused by missense
Cell Tissue Res (2010) 342:1–11 7
mutations ofFgf23 with gain-of-function (ADHR consortium
2000). A part of Fgf23 is cleaved by intracellular proteolytic
processing. The cleaved Fgf23 forms lose their biological
activity. Fgf23 mutations in ADHR result in impaired
proteolytic processing of Fgf23 and increased active Fgf23
levels in serum (Table 2) (White et al. 2001). Phex encodes
endopeptidase. X-linked hypophosphatemia (XLH) is caused
by loss-of-function Phex mutations that increase serum
Fgf23 levels (Table 2) (Johnson et al. 2009). Dmp1 encodes
dentin matrix acidic phosphoprotein, an extracellular matrix
protein. Autosomal recessive hypophosphatemic rickets/
osteomalacia (ARHR) is caused by loss-of-function Dmp1
mutations that increase serum Fgf23 levels (Table 2)
(Lorenz-Depiereux et al. 2006). Dmp1 knockout mouse
phenotypes are similar to ARHR phenotypes. Dmp1/Fgf23
double knockout mouse phenotypes are similar to Fgf23
single knockout mouse phenotypes. These results indicate
that the hypophosphatemia in patients with loss-of-function
Dmp1 mutations is induced by increased serum Fgf23 levels
(Liu et al. 2008). However, the mechanism regulating serum
Fgf23 levels has been unclear.
Reduced Fgf23 signaling also causes human metabolic
disorders. Familial tumoral calcinosis (FTC) is character-
ized by ectopic calcification and hyperphosphatemia.
Missense mutations of Fgf23 with loss-of-function result
in FTC. These mutations destabilize the tertiary structure of
Fgf23 and increase its susceptibility to degradation (Table 2)
(Benet-Pagès et al. 2005). Galnt3 encodes uridine
diphosphate-N-acetly-α-D-galactosamine: polypeptide N-
acetylgalactosaminytransferase. FTC is also caused by loss-
of-function Galnt3 mutations (Table 2) (Topaz et al. 2004;
Frishberg et al. 2005). The enzyme is a Golgi-associated
enzyme that initiates mucin-type O-glycosylation at proteins.
Fgf23 is glycosylated by Galnt3. The O-glycosylation
prevents proteolytic processing of Fgf23 and allows the
secretion of an intact Fgf23 (Kato et al. 2006; Frishberg et al.
2007). Galnt3 knockout mice develop hyperphosphatemia
without apparent calcification. The loss-of-function mutation
of Galnt3 impairs secretion of intact Fgf23, leading to
decreased serum Fgf23 levels and hyperphosphatemia
(Ichikawa et al. 2009). These results provide in vivo evidence
that Galnt3 plays an essential role in the proper secretion of
Fgf23.
In addition to hereditary Fgf23 signaling disorders,
tumors that over-produce Fgf23 also cause metabolic
disorders. TIO is a paraneoplasitc disease characterized by
hypophosphatemia caused by renal phosphate wasting
(Table 2) (Shimada et al. 2001). Serum Fgf23 levels are
also greatly increased in patients with renal failure, partly
owing to decreased renal clearance. These results suggest
that Fgf23 to have a compensatory role in the disease
(Table 2) (Larsson et al. 2003; Imanishi et al. 2004).
Conclusions
Hormone-like Fgfs, Fgf15/19, Fgf21, and Fgf23, are newly
emerging and unique in evolution and function. Although
hormone-like Fgf genes have been identified in most
vertebrates examined, they have not been identified in
invertebrates, indicating that hormone-like Fgfs are
vertebrate-specific. Hormone-like Fgfs mainly act as endo-
crine factors in an Fgfr-dependent manner. Fgf15/19 and
Fgf23 physiologically require βKlotho and αKlotho and as a
Gene Disease Gene mutation Fgf signaling
Hereditary disease
Fgf23 ADHR Gain-of-function mutations of Fgf23 Increase
XLH Loss-of-function mutations of Phex Increase
ARHR Loss-of-function mutations of Dmp1 Increase
FTC Loss-of-function mutations of Fgf23 or Galnt3 Decrease
Paraneoplastic disease
Fgf19 Extrahepatic cholestasis Increase
Fgf23 TIO Increase
Metabolic disease
Fgf19 Chronic hemodialysis Increase
NAFLD Decrease




Fgf23 Renal failure Increase
Table 2 Human diseases
caused by hormone-like Fgf
signaling disorder
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cofactor, respectively. However, Fgf21 might physiologically
require neither. Recent studies have revealed important roles
of hormone-like Fgfs in humans, mice, and zebrafish.
Hormone-like Fgfs participate in metabolism at postnatal
stages, although they also have roles in development at
embryonic stages. Fgf15/19 regulates bile acid metabolism in
the liver. Fgf21 regulates lipid metabolism in the white
adipose tissue. Fgf23 regulates serum phosphate and active
vitamin D levels. Hormone-like Fgf signaling disorders
caused by hereditary diseases or tumors result in metabolic
diseases. In addition, serum hormone-like Fgf levels are
significantly affected by some metabolic diseases. Further
understanding of the roles of hormone-like Fgfs will provide
clues to their roles in metabolism and clinical treatments for
metabolic diseases.
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